The IPO Buzz: Thyroid Biotech Septerna Upsizes IPO by 57 Percent to Raise $275 Million
Septerna Inc. (SEPN Proposed), a Phase 1 biotech focused on developing drugs to treat thyroid and autoimmune disorders, increased its IPO’s size by 57 percent to raise $275 million – up from $175 million originally – in an S-1/A filing early today – Thursday, Oct. 24, 2024. The new terms of Septerna’s IPO are: 15.28 million […]
October 24, 2024 Read More